MedPath

Taizhou Mabtech Pharmaceutical Co., Ltd.

Taizhou Mabtech Pharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

13

Active:0
Completed:7

Trial Phases

3 Phases

Phase 1:9
Phase 3:3
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 1
9 (69.2%)
Phase 3
3 (23.1%)
Phase 4
1 (7.7%)

Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Solid Malignancies
Interventions
First Posted Date
2025-04-18
Last Posted Date
2025-04-18
Lead Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Target Recruit Count
55
Registration Number
NCT06933069

Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis

Phase 3
Not yet recruiting
Conditions
Psoriasis
Interventions
First Posted Date
2024-05-03
Last Posted Date
2024-05-03
Lead Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Target Recruit Count
336
Registration Number
NCT06398652
Locations
🇨🇳

Huashan Hospital, Shanghai, China

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

Phase 3
Recruiting
Conditions
Chronic Spontaneous Urticaria
Interventions
First Posted Date
2024-04-15
Last Posted Date
2024-08-02
Lead Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Target Recruit Count
392
Registration Number
NCT06365879
Locations
🇨🇳

Huashan Hospital, Shanghai, China

Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Biological: Post-change CMAB807
First Posted Date
2024-04-11
Last Posted Date
2024-11-07
Lead Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Target Recruit Count
128
Registration Number
NCT06361355
Locations
🇨🇳

The Second Hospital of Anhui Medical University, Hefei, Anhui, China

Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Phase 4
Recruiting
Conditions
Crohn Disease
Interventions
First Posted Date
2023-06-18
Last Posted Date
2025-05-22
Lead Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Target Recruit Count
30
Registration Number
NCT05906576
Locations
🇨🇳

Beijing Children's Hospital, Capital Medical University, Beijing, China

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.